Gadobutrol: a review in contrast-enhanced MRI and MRA
LJ Scott - Clinical drug investigation, 2018 - Springer
Abstract Intravenous gadobutrol [Gadovist™(EU); Gadavist®(USA)] is a second-generation,
extracellular non-ionic macrocyclic gadolinium-based contrast agent (GBCA) that is …
extracellular non-ionic macrocyclic gadolinium-based contrast agent (GBCA) that is …
High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents
Purpose To determine if a correlation exists between the number of previous enhanced
magnetic resonance (MR) imaging examinations and high signal intensity in the globus …
magnetic resonance (MR) imaging examinations and high signal intensity in the globus …
Evolving Characteristics of Gadolinium‐Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity
E Kanal, JH Maki, P Schramm… - Journal of Magnetic …, 2024 - Wiley Online Library
Gadolinium‐based contrast agents (GBCAs) are widely and routinely used to enhance the
diagnostic performance of magnetic resonance imaging and magnetic resonance …
diagnostic performance of magnetic resonance imaging and magnetic resonance …
Molecular magnetic resonance imaging of tumor response to therapy
Personalized cancer medicine requires measurement of therapeutic efficacy as early as
possible, which is optimally achieved by three-dimensional imaging given the heterogeneity …
possible, which is optimally achieved by three-dimensional imaging given the heterogeneity …
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: comparison between gadobutrol and linear gadolinium …
FG Moser, CT Watterson, S Weiss… - American Journal …, 2018 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: In view of the recent observations that gadolinium
deposits in brain tissue after intravenous injection, our aim of this study was to compare …
deposits in brain tissue after intravenous injection, our aim of this study was to compare …
Targeted gold nanoparticle–oligonucleotide contrast agents in combination with a new local voxel-wise MRI analysis algorithm for in vitro imaging of triple-negative …
R Chauhan, N El-Baz, RS Keynton, KT James… - Nanomaterials, 2019 - mdpi.com
Gold nanoparticles (GNPs) have tremendous potential as cancer-targeted contrast agents
for diagnostic imaging. The ability to modify the particle surface with both disease-targeting …
for diagnostic imaging. The ability to modify the particle surface with both disease-targeting …
Comparison of gadoterate meglumine and gadobutrol in the MRI diagnosis of primary brain tumors: a double-blind randomized controlled intraindividual crossover …
KR Maravilla, D San-Juan, SJ Kim… - American journal …, 2017 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Effective management of patients with brain tumors
depends on accurate detection and characterization of lesions. This study aimed to …
depends on accurate detection and characterization of lesions. This study aimed to …
Macrocyclic paramagnetic agents for MRI: Determinants of relaxivity and strategies for their improvement
A Fringuello Mingo, S Colombo Serra… - Magnetic …, 2017 - Wiley Online Library
Purpose To dissect the contributions to the longitudinal relaxivity (r1) of two commercial
contrast agents (CAs), Gd‐DOTA and Gd‐HP‐DO3A, and to synthesize/characterize a novel …
contrast agents (CAs), Gd‐DOTA and Gd‐HP‐DO3A, and to synthesize/characterize a novel …
The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate …
M Vaneckova, M Herman, MP Smith… - American Journal …, 2015 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Gadobenate dimeglumine (MultiHance) has higher r1
relaxivity than gadoterate meglumine (Dotarem) which may permit the use of lower doses for …
relaxivity than gadoterate meglumine (Dotarem) which may permit the use of lower doses for …
Next-generation cancer magnetic resonance imaging with tumor-targeted alkylphosphocholine metal analogs
RR Zhang, C Choi, CL Brunnquell… - Investigative …, 2022 - journals.lww.com
Objectives In an effort to exploit the elevated need for phospholipids displayed by cancer
cells relative to normal cells, we have developed tumor-targeted alkylphosphocholines …
cells relative to normal cells, we have developed tumor-targeted alkylphosphocholines …